Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some general mechanistic/pharmacologic and formulation claims are broadly consistent with label excerpts, but several liver-condition metabolism and relative-level claims are not supported by the provided label text, and liver-function monitoring/dose adjustment statements are partially inaccurate or unsupported. Also, patent/market exclusivity claims are not supported by the provided FDA labeling excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication that works by inhibiting the production of cholesterol in the liver.
Label mechanism excerpt: 12.1 states LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase. (No explicit statement about 'production of cholesterol in the liver' is quoted in the provided excerpt, but the mechanism supports cholesterol synthesis inhibition.)
Lipitor lowers low-density lipoprotein (LDL) cholesterol levels.
Label clinical pharmacology/studies excerpts: 14.2 states LIPITOR reduces total-C and LDL-C; 1.2. and 1.1 also include reducing LDL-C.
Unsupported Statements
Lipitor is available in tablets and oral solution forms.
Provided label excerpts only list tablet strengths (Section 3) and do not mention an oral solution formulation.
Hepatitis, cirrhosis, and liver cancer can impact the liver's ability to metabolize Lipitor.
The provided excerpts state 'active liver disease' is a contraindication (4.1/8.6) and discuss liver dysfunction monitoring (5.2), but do not support the specific claim that hepatitis/cirrhosis/liver cancer impair metabolism of Lipitor.
In patients with hepatitis, impaired liver metabolism of Lipitor leads to increased levels of the medication in the bloodstream.
No provided label excerpt supports hepatitis-specific increased atorvastatin blood levels due to impaired metabolism.
In patients with hepatitis C, patients have significantly higher levels of atorvastatin than healthy individuals.
No provided label excerpt contains hepatitis C comparative pharmacokinetic results or 'significantly higher levels' statement.
In patients with cirrhosis, impaired liver metabolism of Lipitor leads to increased levels of the medication in the bloodstream.
No provided label excerpt supports cirrhosis-specific pharmacokinetic increases in atorvastatin levels.
In patients with cirrhosis, patients have significantly higher levels of atorvastatin than healthy individuals.
No provided label excerpt contains cirrhosis comparative pharmacokinetic results.
In patients with liver cancer, impaired liver metabolism of Lipitor leads to increased levels of the medication in the bloodstream.
No provided label excerpt supports liver cancer-specific pharmacokinetic increases due to impaired metabolism.
In patients with liver cancer, patients have significantly higher levels of atorvastatin than healthy individuals.
No provided label excerpt contains liver cancer comparative pharmacokinetic results.
Increased levels of Lipitor in the bloodstream may potentially cause adverse effects.
The provided excerpts discuss increased plasma concentrations with CYP3A4 inhibitors and grapefruit juice (7.1-7.2) and discuss adverse reactions generally (6.1/6.2), but do not link 'increased blood levels' to 'adverse effects' in the liver-disease context as stated.
Lipitor usage in patients with liver conditions requires careful monitoring of liver function and adjustment of Lipitor dosage accordingly.
The provided excerpts recommend liver function tests prior to and at 12 weeks after initiation and dose increases (5.2), but they do not state that dosage adjustment is required 'accordingly' for liver conditions; additionally, 'active liver disease' is contraindicated (4.1/8.6).
The patent for Lipitor expired in 2011, allowing generic versions of the medication to enter the market.
FDA prescribing information excerpts provided do not include any patent/market exclusivity statements.
The patent for the extended-release formulation of Lipitor is still in effect.
Provided label excerpts do not mention patent/exclusivity status for any extended-release formulation.
Lipitor has effectiveness and safety that can be compromised in individuals with liver disease.
The label excerpts support liver dysfunction considerations (5.2) and contraindication in active liver disease (4.1/8.6), but the specific phrasing about 'effectiveness and safety…can be compromised' is not directly supported as written.
Contradictions
Low
AI Statement
Lipitor usage in patients with liver conditions requires careful monitoring of liver function and adjustment of Lipitor dosage accordingly.
Label Reference
Contraindication for active liver disease (4.1 'Active liver disease') and contraindication in hepatic impairment (8.6).
Important Omissions
No labeling-supported contraindication detail was provided in the AI claims for 'active liver disease' (including unexplained persistent elevations in hepatic transaminases) and pregnancy/nursing (other contraindications in provided label excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported liver-disease metabolism and comparative exposure claims could mislead interpretation of pharmacokinetics/exposure relationships. The monitoring/dose adjustment claim is not clearly supported and conflicts in part with contraindication of active liver disease.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims about liver disease (hepatitis/cirrhosis/liver cancer) causing increased atorvastatin blood levels and relative exposure differences are not supported by the provided label excerpts; product/formulation and patent/exclusivity statements are also unsupported.
Suggested Improvement
Limit liver-related statements to the provided label-supported concepts: contraindication in active liver disease (4.1/8.6) and liver function testing prior to and at 12 weeks after initiation and any dose increase (5.2). Remove unsupported comparative pharmacokinetic statements and non-label patent/exclusivity assertions. For formulation, only state tablet strengths listed in the provided excerpt (3) unless additional label text supports an oral solution.